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Functionalized protein nanoemulsions by 
incorporation of chemically modified BSA 
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Figueiredo, c Lígia M Saraiva, c Gonçalo J. L. Bernardes, d,e Andreia C. Gomesb 
and Artur Cavaco-Pauloa* 
The incorporation of bioactive compounds in stealth nanoparticles or nanoemulsions enhances 
their half-life in systemic circulation and can overcome the problems associated with the free 
drug. Bovine serum albumin (BSA)-drug conjugates were produced with either methotrexate 
(MTX), a potent anticancer agent, or vancomycin (VCM), a potent antibiotic. Those conjugates 
were used to produce functionalized BSA nanoemulsions in a formulation composed by aqueous 
phase and organic phase. BSA-Folic acid (FA) conjugates were also produced allowing specific 
folate receptor (FR) mediated targeting of cancer cells (KB cell line). All conjugates had similar 
effects either in solution or in the form of nanoemulsions: BSA-MTX as anti-proliferative over 
Caco-2 cell line and BSA-VCM as lower minimum inhibitory concentration (MIC) 
comparatively to VCM solution on Staphylococcus aureus strain Newman. The production of 
nanoemulsions using BSA-drug conjugates for obtaining vectors loaded with stabilized drugs 
offers a good, flexible template for a wide range of medical applications.  
 
Introduction 
Albumin, with a molecular weight of 66.5 kDa, is the most 
abundant plasma protein (35–50 g/L human serum). Small size and 
abundance explain why so many metabolic compounds and 
therapeutic drugs are transported by this protein.1 BSA is widely used 
for drug delivery because of its medical importance, abundance, low 
cost, ease of purification, biodegradability, nontoxicity, non-
immunogenicity, ease to be metabolized in vivo to produce innocuous 
degradation products and solubility in water.2  
The fabrication of albumin-based nanoparticles as controlled 
release drug delivery systems, using specialized nanotechnology 
techniques like desolvation, emulsification, thermal gelation and 
recently nano-spray drying, nab-technology and self-assembly has 
been largely investigated.2-8 Albumin nanoparticles are 
biodegradable, easy to prepare and reproducible in defined sizes, and 
carry reactive groups on their surfaces (amino, thiol and carboxylic 
groups) that can be used for drug conjugation and/or other surface 
modifications.9, 10 Due to a high content of charged amino acids (for 
example lysine, arginine, aspartate and glutamate), the albumin 
nanoparticles allow electrostatic adsorption of positively or negatively 
charged molecules.11 Albumin proteins also offer the advantage of 
easy attachment of ligands/drugs by covalent linkage.12, 13 Moreover, 
albumin nanoparticles represent a promising strategy for targeted drug 
delivery to tumor cells. Their enhanced uptake in solid tumors is 
mediated by binding to albumin-binding proteins, such as membrane-
associated gp60 (albondin) and “secreted protein, acidic and rich in 
cysteine” (SPARC).11  
Here, we describe the design and construction of BSA 
nanoemulsions tailored for specific functions, with improved and 
controlled drug delivery at target sites. We synthesized several BSA-
drug conjugates and produced the corresponding nanoemulsions by 
high pressure homogenization from an initial formulation composed 
by an aqueous phase and a small percentage of organic phase 
(vegetable oil). PEGylated surfactant was introduced in the aqueous 
phase of this initial formulation and small PEGylated nanoemulsions 
were obtained.14 These PEGylated nanoemulsions with specific 
functions, which were obtained by introduction of BSA-FA/drug 
conjugates, were demonstrated to delivery drugs in vitro efficiently.  
All these characteristics of the produced nanoemulsions can 
overcome the problems associated with therapies using free drugs, by 
increasing the half-life of drugs in systemic circulation, protecting 
them from degradation and also reducing potential side effects due to 
the specific cell targeting. 
 
 
Results and discussion 
BSA-FA conjugate and nanoemulsions for specific FR-mediated 
endocytosis 
In order to produce nanoemulsions with the capacity of specific 
cell/tissue targeting, we produced BSA-FA conjugates, which were 
subsequently introduced in nanoemulsion production. The coupling 
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of FA to BSA was performed via carbodiimide linkage15, 16 between 
the carboxylic acid groups of each drug molecules and the 30 to 35 
lysines which have primary amines that can react with the amine 
reactive intermediate compound (Fig. 1).  
 
 
Our chemical synthesis conditions of conjugated BSA-FA 
permitted a good quantitative yield reaction that could be determined 
by absorption spectroscopy. The resulting conjugates contained 35 
moles of FA per 1 mole of BSA, so all the available lysines residues 
of the BSA were coupled to a FA molecule (Supplementary Table S1). 
The purified BSA-FA conjugate solution was added to BSA 
solution (aqueous phase) to produce FA-tagged nanoemulsions, using 
a high pressure homogenizer. The FA acts as targeting agent, since 
FR-alpha is overexpressed on the surface of many human tumor 
cells.17 FA-directed nanoemulsions were produced using varying 
concentrations of BSA-FA conjugate and their physicochemical 
characteristics determined by dynamic light scattering (DLS) (Fig. 2). 
All samples present very similar values of particle size (around 100 
nm), polydispersity index (PDI) and zeta-potential consistently near 
zero, as previously described for the original nanoemulsions.14 
The absorbance spectra of aqueous phase separated from each 
nanoemulsion sample was monitored (ʎ = 350 nm) in order to quantify 
FA that was not used in FA-tagged nanoemulsions production. Upon 
doubling the BSA-FA concentration present in the initial formulation, 
the quantified FA in aqueous phase after nanoemulsions preparation 
did not correlate in the same proportion. In fact, increasing BSA-FA 
conjugate concentration, during production, results in the successful 
incorporation of more FA into the nanoemulsions than expected 
(Supplementary Fig. S1). To determine if increasing BSA-FA 
conjugate for nanoemulsions preparation can more efficiently 
promote specific targeting, we used spectrofluorimetry to quantify 
nanoemulsions internalization by human mouth epidermal carcinoma 
cell line (KB cell line), a widely used model for evaluating FR-alpha 
mediated delivery.18 Fig. 3A shows that FA-nanoemulsions are 
internalized more efficiently and to a higher extent than non-targeted 
nanoemulsions. However, no significant differences were observed 
between nanoemulsions prepared using varying quantities of BSA-FA 
conjugate.  
Internalization assessment of nanoemulsions by confocal laser 
scanning microscopy, using 0.1 mg/mL of BSA-FA conjugate, 
confirmed that KB cells internalized more fluorescent FA-targeted 
nanoemulsions than cells incubated with non-targeted nanoemulsions 
(Fig. 3B). These results suggest that FA-nanoemulsions interact 
efficiently with cellular FR at the cellular surface and promote FR-
mediated endocytosis. This important achievement opens a wide 
range of possibilities for incorporating existing and validated BSA 
bioconjugates, that are typically short-lived in the organism, into 
stable nanoemulsions for targeted therapies with improved efficiency.
Fig. 2 Characterization in terms of size (Z-average) and PDI of BSA nanoemulsions and BSA nanoemulsions prepared using BSA-FA, BSA-
MTX and BSA-VCM conjugates. 
Fig. 1 Scheme of synthesis of BSA-FA and BSA-MTX conjugates. 
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BSA-MTX conjugate and anticancer nanoemulsions  
MTX is a potent anticancer agent of proven benefit in the 
treatment of acute lymphocytic leukemia, lymphomas, 
choriocarcinoma, some solid tumors and was also introduced for the 
therapy of rheumatological disorders.19, 20 However, long-term 
treatment and clinical studies have revealed that the curative effect of 
MTX on cancers was limited because it led to toxic dose-related side 
effects and because of the drug resistance of the tumor cells. The 
improvement of the pharmacokinetic behavior of MTX is therefore 
important to enhance its tumor targeting ability, reduce its toxicity 
and eventually overcome cell resistance. The development of MTX 
conjugates, as well as of nanoparticles containing the drug 
encapsulated could be a successful approach to overcome these 
problems.21-23  
Albumin is a versatile protein carrier for drug targeting and for 
improving the pharmacokinetic profile of small drug molecules, 
peptides or protein based drugs,13, 24 so we tested its conjugation with 
this potent anticancer drug and subsequently encapsulation into 
nanoemulsions. 
The BSA-MTX conjugate25 was also prepared via carbodiimide 
linkage (Fig. 1) and the solution obtained after dialysis showed a ratio 
of 11 moles of MTX per 1 mole of BSA, with estimated 31% of the 
free lysines residues of the protein coupled with MTX 
(Supplementary Table S1). Purified BSA-MTX conjugate was 
introduced in the initial formulation at a 1:2 ratio (m/m) relative to 
the BSA protein, and nanoemulsions were produced by high pressure 
homogenization and further characterized (Fig. 2). These 
nanoemulsions also present very similar values of particle size 
(around 100 nm) and PDI and a drug concentration encapsulated of 
788 μM. Zeta-potential values did not suffer significant variations 
from the empty nanoemulsions. The development of BSA-MTX 
conjugate and nanoemulsions containing this conjugate can overcome 
the problems associated to this drug, namely their important side 
effects. These nanoemulsions produced present suitable 
characteristics as drug delivery systems for administration by 
Fig. 3 Evaluation of nanoemulsions internalization using KB cell line. (A) Relative nanoemulsion internalization between non-targeted 
nanoemulsions and FA-nanoemulsions (prepared using different concentrations of BSA-FA conjugate), determined by incubation of these 
nanoemulsions with KB cells and quantification of nanoemulsions internalized using a spectrofluorimeter (ʎ = 350 nm). Values are the mean 
± SEM of 2 independent experiments. (B) Confocal images of fluorescent nanoemulsions internalization in KB cells. Blue: Hoescht staining 
of cell nucleus; Red: Alexa Fluor 568 Phalloidin staining of cytoscheleton; Green: Fluorescein isothiacianate (FITC) staining of BSA in 
nanoemulsions. 
Page 3 of 8 RSC Advances
R
SC
A
dv
an
ce
s
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
10
 D
ec
em
be
r 2
01
4.
 D
ow
nl
oa
de
d 
by
 T
he
 U
ni
ve
rs
ity
 o
f B
rit
ish
 C
ol
um
bi
a 
Li
br
ar
y 
on
 1
1/
12
/2
01
4 
11
:0
7:
01
.
 
View Article Online
DOI: 10.1039/C4RA13802C
ARTICLE Journal Name 
4 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 2012 
intravenous administration, e.g. small size (≈ 100 nm) and PEGylated 
surface, which can increase the half-life of drugs in systemic 
circulation.14 Additionally, the presence of albumin promotes 
targeting to the tumor site with these nanoemulsions. We then 
compared the cytotoxicity induced by nanoemulsions containing 
MTX and conjugate BSA-MTX with MTX alone at same 
concentration in human colonic epithelial cell line (Caco-2 cell line). 
Fig. 4 shows that nanoemulsions loaded with MTX, BSA-MTX 
conjugate and MTX alone demonstrated very similar values of cell 
viability, supporting another important characteristic for these 
nanoemulsions, the effective release of the drug from nanoemulsions 
in vitro.  
 
 
BSA-VCM conjugate and antimicrobial nanoemulsions 
Staphylococcus aureus is a major human pathogen that causes 
a variety of diseases with significant morbidity and mortality.26, 27 
Glycopeptide antibiotics, such as VCM, are considered first-line 
drugs for treatment of infections caused by methicillin-resistant S. 
aureus (MRSA) and also in patients who are allergic to penicillins.28 
However, the occurrence of vancomycin-resistant microbial 
pathogens has been increasing, posing a serious problem 
worldwide.29, 30 
In order to protect VCM activity when this drug is administered 
intravenously, we also prepared BSA-VCM conjugates and thereafter 
produced nanoemulsions, which present suitable characteristics for 
this particular application.  
A simple and novel BSA-VCM conjugate was synthesized via 
thiol-maleimide addition31 (Fig. 5). The conjugate was obtained by 
reacting in the first step the VCM with the linker 4-(N-
maleimidomethyl) cyclohexane-1-carboxylic acid 3-sulfo-N-
hydroxysuccinimide ester sodium salt, which is reactive between the 
free amino group of the VCM and the succinimide group of the linker. 
The second step of the reaction is carried out between the maleimide-
activated VCM with the only free thiol group present in BSA in 
Cys34.  
Fig. 4 Caco-2 cell line viability after 48h and 72h of contact with 150 μg/mL of nanoemulsions with and without 3.15 μM of MTX, BSA-MTX
conjugate at same concentration of MTX and MTX alone, compared with cells (negative control) and cells incubated with 30% of DMSO
(death control), determined by MTS assay. Values are the mean ± SEM of 2 independent experiments. 
Fig. 5 Scheme of synthesis of BSA-VCM conjugate. 
Page 4 of 8RSC Advances
R
SC
A
dv
an
ce
s
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
10
 D
ec
em
be
r 2
01
4.
 D
ow
nl
oa
de
d 
by
 T
he
 U
ni
ve
rs
ity
 o
f B
rit
ish
 C
ol
um
bi
a 
Li
br
ar
y 
on
 1
1/
12
/2
01
4 
11
:0
7:
01
. 
View Article Online
DOI: 10.1039/C4RA13802C
Journal Name ARTICLE 
This journal is © The Royal Society of Chemistry 2012 J. Name., 2012, 00, 1-3 | 5  
The resulting conjugate was analyzed by MALDI-TOF 
spectrometry which showed that 36% of the BSA molecules were 
modified with a molecule of VCM (Fig. 6). The purified conjugate 
solution showed a ratio of 0.28 moles of VCM per 1 mole of BSA 
(Supplementary Table S1) and was used for further production of 
functionalized BSA nanoemulsions.  
BSA-VCM conjugate nanoemulsions, containing the 
PEGylated surfactant, were characterized in terms of size (Fig. 2) and 
the amount of drug encapsulated was quantified by spectroscopy32 
(45 μg/mL). Zeta-potential values were very similar to what was 
previously recorded. 
The determination of MIC (the lowest concentration of an 
antimicrobial that will inhibit the visible growth of a microorganism 
after overnight incubation) of VCM, BSA-VCM conjugate solution 
and BSA nanoemulsions loaded with VCM was performed using S. 
aureus strain Newman (Table 1).  
 
Table 1 The MIC of BSA solution, VCM solution, BSA-VCM 
conjugate solution, BSA nanoemulsions and BSA-VCM 
nanoemulsions for S. aureus Newman 
Samples MIC (μg/mL) 
BSA solution no effect 
VCM solution 2.5 
BSA-VCM conjugate 1.5 
BSA nanoemulsions no effect 
BSA-VCM nanoemulsions 2 
 
These results demonstrate that the BSA-VCM conjugate as well 
as the derived nanoemulsions potentiate the antimicrobial activity of 
VCM in this S. aureus strain, demonstrating effective release of drug 
from these systems. Moreover, VCM encapsulated in nanoemulsions 
present advantages for administration and protection of the active 
principle that should potentiate therapeutic efficiency in vivo. 
 
Experimental 
Chemical modification of BSA with FA and MTX 
The conjugation process of drug to BSA (Sigma-Aldrich, USA) 
is described as follows: Briefly, each drug molecule, FA (Sigma-
Aldrich, USA) or MTX (Sigma-Aldrich, USA)  was dissolved 
in phosphate buffered saline (PBS, pH 7.4) and ‘activated’ with 
5-fold excess of N-(3-dimethylaminopropyl)-N´-
ethylcarbodiimide hydrochloride (Sigma-Aldrich, USA) and 1-
fold excess of N-hydroxysulfosuccinimide (Sigma-Aldrich, 
USA) for 2 h at room temperature. To each activated drug 
molecule was then added 10 mg/mL of BSA and left reacting 
during 8-10 hours, starting all the reactions in moles ratio of 75:1 
drug to BSA. Excess of drug molecules and by-products were 
removed from conjugated protein using dialysis against PBS 
(pH 7.4) for 8 days.  
 
Chemical modification of BSA with VCM 
The synthetic pathway of BSA-VCM was performed as follows: 
To a solution of VCM (Sigma-Aldrich, USA) (40 mg, 0.27 mM) 
in PBS (pH 7.4), the linker 4-(N-
Maleimidomethyl)cyclohexane-1-carboxylic acid 3-sulfo-N-
hydroxysuccinimide ester sodium salt (sulfo-SMCC) (Sigma-
Aldrich, USA) (16 mg, 0.35 mM) was added and the mixture 
was left stirring during 2h at room temperature. After this time, 
BSA was added in a moles ratio relatively to the VCM of 1:1. 
The reaction mixture was centrifuge (5000 g, 40 min) using the 
centricon tubes (molecular-weight cut-off of 3 kDa, Amicon 
Ultra-15, Millipore) and redispersed with PBS. For MALDI-
TOF analysis the BSA-VCM conjugated and a solution of BSA 
were desalted using PD-10 desalting columns. 
 
Fig. 6 MALDI spectrum of the BSA-Vancomycin conjugate. Analyses were performed on an Axima LNR system (Kratos Analytical,
Shimadzu, Manchester, UK) equipped with a nitrogen laser (337 nm). The mass range from 2 000 to 160 000 Da was recorded by using the
linear mode.  Standard proteins including desalted BSA were used for external calibration of the spectra. Dihydroxybencoic acid (DHB) was
used as MALDI matrix. 
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Quantitation of drug bound to BSA 
Quantitation of drug was performed by measuring the 
absorbance at the maximum wavelength of each drug (FA at 350 
nm and MTX at 372 nm). Quantification of VCM conjugated 
with BSA was performed using MALDI-TOF spectrometry. 
 
Quantitation of BSA 
Quantitation was performed by Bio-Rad protein assay (Bio-Rad 
Laboratories, USA) based on the shift of absorbance maximum 
for an acidic solution of Coomassie Brilliant Blue G-2SO at  595 
nm when binding to protein occurred. 
 
BSA nanoemulsion preparation 
The preparation of BSA nanoemulsions was achieved by 
emulsion using a high-pressure homogenizer (APV-2000, 
Denmark). BSA at concentration of 10 mg/mL and PEGylated 
surfactant at concentration of 5 mg/mL, previously dissolved in 
PBS (pH 7.4), were emulsified with the organic solvent 
(vegetable oil) by subjecting the mixture to high pressure 
homogenization. BSA-FA conjugate, previously prepared, was 
incorporated at different ratio (m/m), relatively to BSA, to 
aqueous phase and nanoemulsions tagged with FA were 
obtained. BSA-MTX conjugate solution, previously prepared, 
was also added to the aqueous phase at a 1:2 ratio (m/m) relative 
to the BSA protein.  BSA-VCM conjugate solution, previously 
prepared, was used as total aqueous phase for nanoemulsions 
production. After synthesis, the nanoemulsions-containing 
phase was collected by centrifugation (1000 g and during 45 
minutes) using centricon tubes (molecular weight cut-off of 100 
kDa) (Amicon Ultra-15, Millipore). The free protein conjugates 
in the aqueous phase after separation was analyzed for 
quantification of protein and of different ligands conjugated with 
BSA. 
 
Determination of size and polydispersity index 
The nanoemulsions were analyzed for their size distribution, at 
pH 7.4 (PBS buffer) and at 25ºC, using dynamic light scattering 
in a Malvern zetasizer NS, by photon correlation spectroscopy 
(PCS). The protein concentration was kept constant at 10 
mg/mL. The values for viscosity and refractive index were taken 
as 0.890 cP and 1.330, respectively. Each sample was measured 
in triplicate and results are presented as mean value ± standard 
deviation.  
 
Cells and culture conditions 
Human mouth epidermal carcinoma cells (KB cell line) (ATCC, 
CCL-17) and human colonic epithelial cells (Caco-2 cell line) 
(ATCC, HTB-37) were obtained from American Type Culture 
Collection (LGC Standards, UK). KB cells line were maintained 
in Roswell Park Memorial Institute (RPMI)-1640 Medium 
(Sigma-Aldrich, USA) supplemented with 10% (v/v) of fetal 
bovine serum (FBS) (Sigma-Aldrich, USA), 1% (v/v) of 
penicillin/streptomycin solution (Sigma-Aldrich, USA), 2 mM 
of L-glutamine (Sigma-Aldrich, USA) and 2 g/L of sodium 
bicarbonate (Sigma-Aldrich, USA). Caco-2 cells line were 
routinely grown in Dulbecco´s Modified Eagle’s Medium 
(DMEM) (Sigma-Aldrich, USA) containing  2 mM of L-
glutamine, 4.5 g/L of glucose, 1.5 g/L of sodium bicarbonate, 
supplemented with 20% (v/v) of FBS, 1% (v/v) of 
penicillin/streptomycin solution and 1% (v/v) of Minimum 
Essential Medium (MEM) non-essential amino acids (Sigma-
Aldrich, USA). All these adherent cell lines were grown in T75 
flasks (TPP, Switzerland) as a monolayer. 
 
Quantification of nanoemulsions internalization 
KB cells were seeded in 6-well plates (TPP, Switzerland) at a 
density of 2×105 cells/well and incubated overnight to promote 
cell adhesion. Solutions of nanoemulsions with and without 
BSA-FA conjugate were prepared in folate-free Hanks’ 
Balanced Salt solution (HBSS medium) (Lonza, Belgium). Cells 
were washed twice with PBS (pH 7.4) and nanoemulsions 
solutions at concentration of 300 μg/ml were added to 
monolayer of cells and incubated at 37ºC during 2 hours. After 
three further washing steps with cold PBS, cells were lysed with 
one solution of Tris-HCl buffer at 10 mM and the fluorescence 
of these solutions was then analyzed with an Horiba Jobin Yvon 
Spex Fluorolog-3 spectrofluorimeter using the λexc = 480 nm, 
scanning within a wavelength range of 490 nm to 650 nm. 
Calibration curves of each solution of tested nanoemulsions 
were also measured. 
 
Observation of nanoemulsions internalization by confocal 
microscopy 
KB cells were seeded at a density of 5×104 cells/well and 
incubated overnight to promote cell adhesion. Solutions of 
nanoemulsions with and without BSA-FA conjugate were 
prepared in HBSS medium. Cells were washed twice with PBS 
buffer and then 300 μg/mL nanoemulsion suspensions were 
added to the monolayer, which was incubated at 37ºC for 2 
hours. After three further washing steps with cold PBS buffer, 
cells were fixed with 500 μL of paraformaldehyde 4% (v/v) for 
30 minutes. The cells were further washed twice with PBS and 
incubated with Triton 0.1% (v/v) solution, in order to promote 
the cells permeabilization for phalloidin staining. After two 
washing steps with PBS, fixed cells were incubated with 5 
units/mL of Alexa Fluor 568 Phalloidin (Molecular Probes by 
Life Technologies, USA). The coverslips were put on slides 
coated with 2 μL of Permafluor (Thermo Scientific, United 
Kingdom) with 5 μg/mL of Hoescht (Molecular Probes by Life 
Technologies, USA). Microscopic observations were done with 
inverted Zeiss confocal laser scanning microscope (CLSM; 
Olympus Fluoview FV1000). 
 
Cell viability assay 
Cell viability was studied using the Promega CellTiter 96® 
AQueous Non-Radioactive Cell Proliferation (MTS) assay 
(Promega, USA). Caco-2 cells were seeded in 96-well tissue 
culture polystyrene plates (TPP, Switzerland) at a density of 
1×104 cells/well and incubated overnight to promote cell 
adhesion. Cells were incubated with 150 μg/mL of 
nanoemulsions with and without 3.15 μM of MTX, with BSA-
MTX conjugate at same concentration of MTX and with MTX 
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alone. Two incubation times (48 and 72 hours) were tested and 
then a MTS mixture (20 μL/well) was added and the cells 
incubated for 4 hours at 37ºC. After this period, the plates were 
placed on a microwell plate reader Spectra MAX 340PC and the 
absorbance of the formazan product was read at 490 nm. Cell 
viability was expressed as a percentage relative to the negative 
control (untreated control cells).  
 
Determination of the MIC of BSA-VCM conjugate and BSA-
VCM nanoemulsions 
MIC was determined by the tube dilution test. Briefly, 2 mL of 
Luria-Bertani (LB) medium was inoculated with an overnight 
culture of S. aureus Newman to give an optical density at 600 
nm of 0.01. Concentrations of several VCM conjugates, 
nanoemulsions prepared using conjugates and respective 
controls, ranging from 0.25 to 3 μg/ml, were added to the diluted 
suspensions in 24-well plates, which were incubated for 24 h at 
37°C. The concentration of VCM in the first well in the series 
with no sign of visible growth was reported as the minimal 
inhibitory concentration. The experiments were performed for 
two biological samples. 
 
Conclusions 
We describe the design and straightforward production by high 
pressure homogenization of functionalized nanoemulsions using 
chemically modified BSA, with a wide range of applications. 
Including BSA-FA conjugate in the initial formulation allowed the 
production of FA-tagged nanoemulsions that demonstrated specific 
FR-mediated targeting in KB cancer cell line. BSA conjugated with 
two different drugs (MTX and VCM) also demonstrated good results 
when applied in vitro. MTX encapsulated in nanoemulsions present 
numerous advantages to using the drug alone or the MTX-
bioconjugates, such as protection of the bioactive compound from 
degradation in vivo and improved half-life in systemic circulation. 
The combination of such advantages would overcome severe side 
effects associated with MTX treatment. Nanoemulsions prepared 
with BSA-VCM led to a significant reduction of MIC in S. aureus 
strain Newman. These results showed that the BSA-VCM 
bioconjugate, alone or formulated in a nanoemulsion, can potentiate 
the antimicrobial effect of this drug, reducing the need for high dose 
therapy and associated problems.  
Thus, the development of these BSA-FA/drugs conjugates and 
their use in the production of BSA nanoemulsions previously 
developed, which are small and stealth nanoparticles,14 allowed the 
construction of functionalized, effective nanoemulsions. The 
approach here described results in functionalized nanoemulsions that 
are suitable for drug delivery application in a very wide range of 
clinical settings. 
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